Product image of Liperial (Fenofibrate) supplied by GNH India

Liperial

Active Ingredient:
Fenofibrate
Origin:
EU

Liperial (Fenofibrate)

Fenofibrate, the active ingredient in Liperial, is a fibric acid derivative presented as an oral tablet for oral use. It belongs to the lipid‑lowering therapeutic class and is marketed in the European Union for the treatment of hypertriglyceridemia, mixed dyslipidemia and hypercholesterolemia in adult patients, aiming to improve lipid profiles and reduce cardiovascular risk.

GNH India supplies Liperial as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres and clinics worldwide, providing reliable sourcing and regulatory‑aligned distribution and ensuring consistent quality across global markets.

Manufacturer / TM Owner

Viatris Healthcare Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Fenofibrate is used to manage disorders of lipid metabolism, particularly elevated triglyceride and cholesterol levels.

  • Hypertriglyceridemia: lowers high triglyceride concentrations in the blood.
  • Mixed dyslipidemia: improves both triglyceride and LDL/HDL cholesterol profiles.
  • Hypercholesterolemia: reduces total and LDL cholesterol levels, supporting overall lipid control.

How It Works

  • Fenofibrate activates peroxisome proliferator‑activated receptor alpha (PPARα), a nuclear transcription factor that up‑regulates genes involved in fatty acid oxidation. This activation increases lipolysis, enhances clearance of triglyceride‑rich lipoproteins, reduces hepatic VLDL synthesis, and raises HDL cholesterol, collectively improving plasma lipid profiles.

Side Effects

Fenofibrate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Gastrointestinal discomfort: nausea, abdominal pain, dyspepsia.
  • Headache: mild to moderate intensity.
  • Muscle pain (myalgia): aching or soreness of muscles.
  • Elevated liver enzymes: increased ALT or AST levels.
  • Elevated serum creatinine: mild rise in kidney function markers.
  • Skin rash: mild dermatologic irritation.

Serious or Rare Side Effects

  • Rhabdomyolysis: severe muscle breakdown with potential kidney injury.
  • Hepatotoxicity: significant liver injury indicated by marked enzyme elevations.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Gallstones: formation of biliary sludge or stones.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor relevant parameters.

  • Renal impairment: assess kidney function and adjust therapy as needed.
  • Hepatic disease: monitor liver enzymes regularly.
  • Pregnancy and lactation: use only if potential benefits outweigh risks.
  • Drug interactions: review concomitant medications for possible interactions.
  • Cardiovascular disease: exercise caution in patients with coronary artery disease.
  • Store at ambient temperature: keep in original container, protect from moisture.

Avoid Interactions

Fenofibrate can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • Gemfibrozil: markedly increases risk of myopathy.
  • Cyclosporine: may raise fenofibrate plasma concentrations.
  • Anticoagulants (e.g., warfarin): can enhance anticoagulant effect.

Moderate Interactions (Monitor Closely)

  • Statins: potential for myopathy; monitor creatine kinase.
  • Oral contraceptives: may elevate triglyceride levels.
  • Thiazide diuretics: can affect lipid parameters and renal handling.

Frequently Asked Questions

Liperial contains fenofibrate and is prescribed to lower elevated triglyceride and cholesterol levels in adults with hypertriglyceridemia, mixed dyslipidemia, or hypercholesterolemia, helping improve overall lipid profiles and reduce cardiovascular risk.

Fenofibrate activates the nuclear receptor PPARα, which increases the breakdown of fatty acids, enhances clearance of triglyceride‑rich lipoproteins, reduces hepatic VLDL production, and raises HDL cholesterol, collectively leading to lower blood triglycerides and cholesterol.

The specific dose of Liparial is determined by the prescribing clinician based on the patient’s condition, laboratory values, and overall health status. Dosage adjustments may be needed for renal or hepatic impairment.

The safety of fenofibrate in pregnancy and lactation has not been established. It should be used only if the potential benefits justify the potential risks to the fetus or infant, and only under medical supervision.

To place an order, submit an enquiry on the Liparial product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Fenofibrate belongs to the fibric acid class, which primarily lowers triglycerides and modestly raises HDL. This differs from statins, which mainly reduce LDL cholesterol, and from niacin, which also raises HDL. Choice of therapy depends on the patient’s lipid profile and clinical goals.

Store Liparial at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Liparial is taken orally, usually with a meal to improve absorption. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include rhabdomyolysis (severe muscle breakdown), hepatotoxicity (significant liver injury), and severe allergic reactions such as anaphylaxis. Patients should report unexplained muscle pain, dark urine, jaundice, or signs of an allergic response promptly.

Liparial should be avoided in patients with known hypersensitivity to fenofibrate or other fibric acid derivatives, those with severe liver disease, and individuals taking contraindicated medications such as gemfibrozil. Caution is also advised for patients with renal impairment or active gallbladder disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Fenofibrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT